CT102 (Cura Therapeutics)

CT102 is a preclinical-stage engineered recombinant protein immunotherapy being developed by Cura Therapeutics for the treatment of viral infections. Developed using Cura's proprietary multimodal fusion protein platform, CT102 is designed to leverage cytokines and immune receptors to create multifunctional proteins with novel immunomodulatory properties. The drug is intended to function as an anti-viral immunotherapy, potentially addressing multiple disease mechanisms simultaneously. While the specific viral indication, molecular targets, and detailed mechanism of action have not been publicly disclosed, the candidate is being positioned for use as either a standalone treatment or in combination with existing standard-of-care therapies.